Comments
Jubilant Life Sciences on Tuesday reported a more than 22 per cent jump in its net profit for the quarter-ended June 30, 2016, at ₹161.6 crore. The company had registered profit of ₹131.93 crore during the corresponding quarter of the previous fiscal.
The company’s income, however, saw a small dip during the quarter at ₹1,419.53 crore against ₹1,445.7 crore during the June quarter last year.
In a joint statement, Shyam S Bhartia, Chairman, and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences, said: “We have started the fiscal year 2017 on a positive note delivering strong performance in the pharmaceuticals segment, which contributed about 70 per cent of the company’s operating profit… Our company has built a robust long-term sustainable business model with the growth engine of pharmaceuticals and drug discovery solutions segments.”
The company has posted a 7 per cent increase in revenues from the pharmaceutical segment at ₹752 crore, 67 per cent of which came from North America.
Jubilant Life Science’s scrip closed at ₹341.9, higher by 3.61 per cent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.